288 related articles for article (PubMed ID: 12816859)
1. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
Gringeri A; Mantovani LG; Scalone L; Mannucci PM;
Blood; 2003 Oct; 102(7):2358-63. PubMed ID: 12816859
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.
Stieltjes N; Torchet MF; Misrahi L; Roussel-Robert V; Lambert T; Guérois C; Bertrand MA; Briquel ME; Borel-Derlon A; Dirat G
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):4-11. PubMed ID: 20527720
[TBL] [Abstract][Full Text] [Related]
3. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
4. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
[TBL] [Abstract][Full Text] [Related]
5. Outcome measures for adult and pediatric hemophilia patients with inhibitors.
Hermans C; Auerswald G; Benson G; Dolan G; Duffy A; Jiménez-Yuste V; Ljung R; Morfini M; Lambert T; Osooli M; Zupančić Šalek S
Eur J Haematol; 2017 Aug; 99(2):103-111. PubMed ID: 28332238
[TBL] [Abstract][Full Text] [Related]
6. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Thorat T; Neumann PJ; Chambers JD
J Manag Care Spec Pharm; 2018 Jul; 24(7):632-642. PubMed ID: 29952709
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
8. Participation in research: the economic advantages in a haemophilia research population.
Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
[No Abstract] [Full Text] [Related]
9. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.
Ekert H; Brewin T; Boey W; Davey P; Tilden D
Haemophilia; 2001 May; 7(3):279-85. PubMed ID: 11380632
[TBL] [Abstract][Full Text] [Related]
10. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic factor replacement in hemophilia.
Carcao MD; Aledort L
Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
[TBL] [Abstract][Full Text] [Related]
12. Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.
Weatherall J; Barnes N; Brown C; Préaud E
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):411-4. PubMed ID: 21831021
[TBL] [Abstract][Full Text] [Related]
13. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
14. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
16. The socioeconomic burden of patients affected by hemophilia with inhibitors.
D'Angiolella LS; Cortesi PA; Rocino A; Coppola A; Hassan HJ; Giampaolo A; Solimeno LP; Lafranconi A; Micale M; Mangano S; Crotti G; Pagliarin F; Cesana G; Mantovani LG
Eur J Haematol; 2018 Oct; 101(4):435-456. PubMed ID: 29889317
[TBL] [Abstract][Full Text] [Related]
17. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
18. Prophylaxis in children with hemophilia: is it the optimal treatment?
Lusher JM
Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
[No Abstract] [Full Text] [Related]
19. Is haemophilia prophylaxis achievable in the context of self-sufficiency?
Nilsson IM
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S71-5. PubMed ID: 7795143
[TBL] [Abstract][Full Text] [Related]
20. Current issues in prophylactic therapy for persons with hemophilia.
Dunn AL; Abshire TC
Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]